万孚生物
(300482)
| 流通市值：71.99亿 | | | 总市值：78.51亿 |
| 流通股本：4.29亿 | | | 总股本：4.68亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,038,506,474.79 | 581,742,751.09 | 2,086,830,072.65 | 1,690,175,392.8 |
| 营业收入 | 1,038,506,474.79 | 581,742,751.09 | 2,086,830,072.65 | 1,690,175,392.8 |
| 利息收入 | - | - | - | 0 |
| 已赚保费 | - | - | - | 0 |
| 手续费及佣金收入 | - | - | - | 0 |
| 二、营业总成本 | 924,188,328.32 | 491,970,446.34 | 2,249,566,528.36 | 1,602,538,044.34 |
| 营业成本 | 378,751,665.98 | 213,831,615.49 | 897,853,120.8 | 671,032,425.44 |
| 利息支出 | - | - | - | 0 |
| 手续费及佣金支出 | - | - | - | 0 |
| 退保金 | - | - | - | 0 |
| 赔付支出净额 | - | - | - | 0 |
| 提取保险合同准备金净额 | - | - | - | 0 |
| 保单红利支出 | - | - | - | 0 |
| 分保费用 | - | - | - | 0 |
| 税金及附加 | 15,739,983.87 | 8,280,208.58 | 15,022,930.25 | 7,442,208.33 |
| 销售费用 | 279,377,823.88 | 137,420,185.44 | 658,840,553.03 | 484,552,232.7 |
| 管理费用 | 78,066,328.02 | 40,391,365.18 | 299,448,333.58 | 145,936,843.23 |
| 研发费用 | 137,847,320.85 | 73,647,885.55 | 336,700,613.8 | 265,096,901.5 |
| 财务费用 | 34,405,205.72 | 18,399,186.1 | 41,700,976.9 | 28,477,433.14 |
| 其中:利息费用 | 14,683,761.07 | 7,448,942.47 | 31,138,596.21 | 24,137,739.05 |
| 其中:利息收入 | 3,914,088.94 | 1,627,195.86 | 7,673,544.63 | 4,917,784.82 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 13,030,142.94 | 6,747,243.28 | 13,639,950.87 | 25,052,801.51 |
| 加:投资收益 | 7,683,449.31 | 3,137,777.57 | 39,786,048.52 | 13,744,980.69 |
| 净敞口套期收益 | - | - | - | 0 |
| 汇兑收益 | - | - | - | 0 |
| 资产处置收益 | 0 | - | 318,789.99 | 583.1 |
| 资产减值损失(新) | 0 | -1,000 | -23,709,931.39 | -7,835,193.97 |
| 信用减值损失(新) | -4,060,710.91 | -7,893,474.9 | -951,533.16 | -5,129,642.63 |
| 其他收益 | 11,596,576.44 | 6,154,805.59 | 23,237,287.78 | 16,273,070.84 |
| 四、营业利润 | 142,567,604.25 | 97,917,656.29 | -110,415,843.1 | 129,743,948 |
| 加:营业外收入 | 1,158,445.95 | 765,368.73 | 2,898,040.14 | 2,534,787.02 |
| 减:营业外支出 | 3,172,265.32 | 1,504,483.05 | 7,175,503.97 | 5,659,011.27 |
| 五、利润总额 | 140,553,784.88 | 97,178,541.97 | -114,693,306.93 | 126,619,723.75 |
| 减:所得税费用 | 15,398,520.82 | 11,056,073.74 | -45,034,833.47 | 184,947.97 |
| 六、净利润 | 125,155,264.06 | 86,122,468.23 | -69,658,473.46 | 126,434,775.78 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 125,155,264.06 | 86,122,468.23 | -69,588,874.23 | 126,434,775.78 |
| 终止经营净利润 | - | - | -69,599.23 | 0 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 122,522,800.44 | 84,399,549.76 | -63,024,899.74 | 133,739,825.24 |
| 少数股东损益 | 2,632,463.62 | 1,722,918.47 | -6,633,573.72 | -7,305,049.46 |
| 扣除非经常损益后的净利润 | 89,179,567.16 | 66,708,002.52 | -12,969,757.16 | 82,641,577.55 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.26 | 0.18 | -0.13 | 0.28 |
| (二)稀释每股收益 | 0.26 | 0.18 | -0.13 | 0.28 |
| 八、其他综合收益 | 7,017,702.46 | 18,116,871.33 | 42,498,484.27 | -66,202.61 |
| 归属于母公司股东的其他综合收益 | 7,017,702.46 | 18,116,871.33 | 42,498,484.27 | -66,202.61 |
| 九、综合收益总额 | 132,172,966.52 | 104,239,339.56 | -27,159,989.19 | 126,368,573.17 |
| 归属于母公司股东的综合收益总额 | 129,540,502.9 | 102,516,421.09 | -20,526,415.47 | 133,673,622.63 |
| 归属于少数股东的综合收益总额 | 2,632,463.62 | 1,722,918.47 | -6,633,573.72 | -7,305,049.46 |
| 公告日期 | 2026-08-24 | 2026-04-23 | 2026-04-23 | 2025-10-27 |
| 审计意见(境内) | | | 标准无保留意见 | |